Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. by Davidson, M & Starling, N
© 2016 Davidson and Starling. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
OncoTargets and Therapy 2016:9 7235–7245
OncoTargets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
7235
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OTT.S100643
Trastuzumab in the management of gastroesophageal  
cancer: patient selection and perspectives
Michael Davidson
Naureen Starling
Department of Gastrointestinal 
Oncology, The Royal Marsden 
Hospital NHS Foundation Trust, 
London, UK
Abstract: The addition of trastuzumab to the treatment of a subset of patients with advanced 
gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to 
confer clinical benefit; however, questions remain over the optimal methods for defining and 
selecting such patients. This review provides an overview of current standards for assessing 
HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal 
cancers and the challenges and potential future directions in optimal patient selection for 
HER2-targeted therapy.
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Introduction
Gastroesophageal (GE) cancers are among the leading causes of cancer death 
worldwide.1 The outlook for metastatic disease remains bleak, with median overall 
survival (OS) generally not reaching more than 1 year in the majority of clinical trials.2 
The anti-HER2 humanized monoclonal antibody trastuzumab remains a landmark in 
anticancer drug discovery. It was developed jointly by Genentech and the University 
of California in the 1990s and gained regulatory approval for breast cancer treatment 
in 1998.3,4 It was later approved in gastric and gastroesophageal junction (GEJ) adeno-
carcinoma after the ToGA trial showed a survival benefit for a subset of HER2-positive 
patients in conjunction with first-line chemotherapy.5 The only approved indications 
remain in GE adenocarcinomas and breast cancers; however, there is growing interest 
in its potential utility for “molecularly triaged” subsets of other solid organ tumors 
that display HER2 positivity, such as lung and colorectal cancers, although such work 
remains exploratory.6,7 It is generally well tolerated, with commonly reported side 
effects including flu-like symptoms and mild gastrointestinal upset.8 A well-character-
ized and potentially more serious complication is cardiac dysfunction characterized by 
decline in ejection fraction. This is a rare and normally reversible side effect, occurring 
in 2%–7% of patients treated with trastuzumab alone, although the risk is increased 
when given in conjunction with cardiotoxic chemotherapies.9 A number of further 
HER2-targeting agents have been tested in both early- and late-stage GE cancer with 
generally disappointing results thus far.10–13 Key to the successful clinical application of 
HER2-directed therapy is appropriate, robust and reproducible patient selection. In the 
field of gastric cancer, there is some controversy over optimal immunohistochemical 
(IHC) and in situ hybridization (ISH) genetic analysis, and differing emphasis on the 
relative importance of protein expression versus gene amplification has led to diver-
gent global standards in the definition of HER2 positivity. This review describes the 
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background of HER2 targeting in gastric cancer and discusses 
some of the current issues and potential future directions in 
defining and treating HER2-positive patients.
Current treatment landscape
Treatment for advanced GE cancer remains primarily che-
motherapy based; however, the recent regulatory approval 
of ramucirumab and a growing interest in immunotherapeu-
tic approaches are beginning to expand non-chemotherapy 
treatment options. There is little consensus on optimal 
first-line chemotherapy, and standard regimes normally 
consist of a fluoropyrimidine combined with a platinum 
agent, with the possible addition of either an anthracycline 
or a taxane.2,14,15 Irinotecan is more commonly used as a 
second-line therapy; however, several studies have sug-
gested that FOLFIRI (irinotecan with 5-fluorouracil [FU]) 
also has activity in the first line.16,17 Second-line chemo-
therapy with irinotecan, docetaxel and paclitaxel have all 
demonstrated a survival advantage over best supportive 
care (BSC) alone.18–20
Phase III trials of ramucirumab have demonstrated signifi-
cant efficacy in the second-line setting both as monotherapy 
and in combination with paclitaxel.21,22 Evaluation in the 
first-line setting is ongoing with the phase III RAINFALL 
study (NCT02314117). As with other cancer types, there is 
growing interest in immunotherapeutic treatment approaches, 
primarily focused on the use of checkpoint inhibitors. The 
KEYNOTE 012 study reported response rates (RRs) of 22% 
with pembrolizumab in a heavily pretreated population, 
and further trials are in progress in both first-line combina-
tion with chemotherapy (NCT02335411) and second-line 
comparison with paclitaxel (NCT02370498). Combination 
blockade of both PD-1 and VEGFR2 appeared to show a 
synergistic effect in preclinical models, and a phase I study 
is currently evaluating the combination of pembrolizumab 
and ramucirumab (NCT02443324).23
HER2 in gastric and esophageal 
cancers
HER2 belongs to the EGFR family of transmembrane 
tyrosine kinase receptors. Unlike other receptors in the 
family, it has no known activating ligand and must het-
erodimerize with EGFR, HER3 or HER4 to trigger trans-
phosphorylation and activation of downstream PI3K or 
MAPK signaling pathways.24 When overexpressed, HER2 
can homodimerize, giving rise to ligand-independent sig-
naling.25 The reported frequency of HER2 overexpression 
in GE cancer varies widely in the literature, ranging from 
4% to .50% in some reports.26–29 The lowest frequency 
is reported in distal tumors and the highest in tumors of 
the GEJ.28,29 Rates of HER2 expression in squamous cell 
cancers of the upper esophagus are low, and as a result, the 
application of HER2-targeted therapy has generally been 
limited to adenocarcinomas of the lower esophagus and 
stomach.30 An association with intestinal histology has been 
consistently reported, with HER2 amplification uncommon 
in diffuse gastric cancers.28 A recent case series of 1461 
Japanese patients reported an HER2 positivity rate of 21%. 
Multiple logistic regression analysis identified intestinal type, 
hepatic metastasis and absence of peritoneal metastasis as 
significant independent factors related to HER2 positivity.31 
The association between HER2 expression and prognosis in 
GE cancer is uncertain; however, a number of studies have 
now shown HER2 to be a negative prognostic factor associ-
ated with more aggressive biological behavior and higher 
frequencies of recurrence.27,32,33 A 2012 systematic review 
of 42 studies concluded that HER2 positivity was associated 
with decreased survival and adverse clinicopathological 
features, including early progression, serosal invasion and 
more advanced stage.27 Such results are consistent with breast 
cancer, where HER2 positivity is known to be an adverse 
prognostic factor.34
Researchers at The Cancer Genome Atlas (TCGA) 
recently undertook an analysis of gastric adenocarcinoma 
utilizing next-generation sequencing (NGS) techniques, 
describing four distinct subtypes Epstein–Barr virus (EBV)-
positive tumors, microsatellite-unstable tumors, genomically 
stable tumors and tumors with chromosomal instability 
(CIN).35 HER2 amplification was most commonly seen in CIN 
tumors, with less common prevalence in the EBV-positive 
and genomically stable subgroups. No microsatellite-unstable 
tumors were HER2 amplified, although some demonstrated 
HER2 missense mutations. The CIN subtype of tumors most 
associated with HER2 positivity are characterized by CIN 
and recurrent amplification of other potentially clinically 
relevant receptor tyrosine kinases.35 The interaction between 
HER2 detection and targeting with other altered tyrosine 
kinase signaling pathways seen in this subset of tumors is 
currently unclear.
Defining HER2 positivity
Standardized protocols for evaluating and defining HER2 
positivity were originally developed for breast cancer, with 
the most widely adopted being the American Society of 
Clinical Oncology (ASCO)/College of American Patholo-
gists (CAP) clinical practice guidelines.36 Testing is through 
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either IHC assessment of protein expression using antibody 
staining or ISH assessment of gene amplification. Tradition-
ally, the most commonly utilized method of gene amplifica-
tion is fluorescent ISH (FISH), a cytogenetic technique that 
uses customized fluorescent probes that bind to specific DNA 
sequences with a high degree of sequence complementarity.37 
Further emerging techniques include chromogenic and 
silver-enhanced ISH (CISH/SISH). CISH uses a peroxidase 
enzyme-labeled probe for chromogenic detection by diamino-
benzidine, while SISH uses the same technique with a silver-
based detection system.38 Because these processes do not 
involve fluorescent dye, a standard bright-field microscope 
can be used, circumventing some of the technical difficulties 
associated with FISH.38 An additional technique now becom-
ing more widespread is dual-color, dual-hapten, bright-field 
ISH (DDISH). This is an automated process that again can 
be evaluated by conventional microscopy. In contrast to 
SISH, which requires two separate slides to detect HER2 and 
CEP17, DDISH uses double-stranded dual-hapten probes to 
detect both markers on a single slide. Concordance between 
FISH and DDISH HER2 amplification results has been found 
to be high.39 Figure 1 illustrates DDISH HER2 positivity in 
a gastric cancer specimen.
In both breast and GE cancers, protein expression is 
categorized into IHC 0, 1+, 2+ and 3+ based upon a score 
incorporating both the intensity of staining and the percent-
age or number of cancer cells demonstrating that intensity, 
however, important differences between the two tumor types 
have led to modifications in their respective scoring systems. 
The membranous distribution of protein within breast cancer 
cells is predominantly circumferential (Figure 2), and breast 
tumors are defined as IHC 3+ if there is complete circum-
ferential membrane staining in .10% of tumor cells, IHC 
2+ if there is incomplete circumferential membrane staining 
in .10% or complete staining within ,10% of cells and IHC 
1+ if there is incomplete faint membrane staining.36 HER2 
protein expression in GE cancer tends to spare the digestive 
luminal membrane, resulting in membrane staining that is 
not completely circumferential but is instead predominantly 
basolateral or lateral (Figure 3A and B).40 Furthermore, a 
greater degree of intratumoral HER2 heterogeneity has been 
reported in GE specimens, with the presence of variable focal 
areas of HER2 positivity often seen (Figure 4).41
Given these differences, a modified IHC scoring system 
for gastric cancer was developed for the ToGA trial and 
validated on 168 specimens in a pre-ToGA study, with high 
concordance found between the modified IHC criteria and 
ISH gene amplification results.42 This was subsequently vali-
dated in a larger dataset and has now been widely adopted by 
clinicians and institutions worldwide.43 The refined GE scor-
ing system does not require complete circumferential homo-
geneity of staining, and the percentage of cancer cells that 
are required to show HER2 expression is lower. A specimen 
showing weak/moderate or strong complete circumferential 
“or” basolateral staining is designated as 2+ or 3+, respec-
tively. The scoring system also takes into account the more 
heterogeneous patterns of HER2 positivity in GE cancer by 
distinguishing between surgical and biopsy specimens. When 
evaluation is performed on surgical samples, a cutoff point 
of 10% of cells in the entire specimen is necessary, whereas 
for endoscopic biopsy samples a single cluster of at least five 
positive cells is sufficient.43 The sensitivity and specificity of 
these modified GE criteria for detecting HER2 gene amplifi-
cation were compared with the ASCO/CAP breast guidelines 
in a study of 1059 primary gastric adenocarcinomas, which 
included 123 HER2-amplified tumors.44 The modified criteria 
Figure 1 DDiSH evaluation of HER2 amplification in gastric cancer showing both 
chromosome 17 (red signals) and HER2 probes (black signals).
Abbreviation: DDISH, dual-color, dual-hapten, bright-field in situ hybridization.
Figure 2 HeR2 staining in breast cancer illustrating circumferential membranous 
staining pattern.
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demonstrated significantly higher sensitivity for detecting 
gene amplification as compared with the breast criteria (66% 
vs 48%, respectively). Both sets of criteria demonstrated an 
equally high specificity for correctly identifying negative 
(IHC 0 and 1+) patients. Formal guidelines for HER2 scoring 
in gastrointestinal cancer are currently under development 
by a collaboration between ASCO/CAP and the American 
Society for Clinical Pathology (ASCP); however, they have 
not been published at the time of writing.45 Comparison of 
differing HER2 IHC assessment criteria in breast and GE 
cancers is given in Table 1.
ISH results are reported as the ratio between HER2 and 
the chromosome 17 enumeration probe (CEP17) within the 
nucleus of ∼20 cancer cells. The definition of positivity in 
both breast and GE cancers is an HER2/CEP17 ratio of $2. 
However, account is also taken of average HER2 copy num-
ber per cell and ISH positivity also includes an HER2/
CEP17 ratio of ,2 if the HER2 copy number is $6. ISH is 
equivocal if the HER2/CEP17 ratio is ,2 with a copy number 
between 4 and 6 and ISH is negative if the HER2/CEP17 ratio 
is ,2 and copy number is ,4.36
Clinical role of HER2-directed 
therapies in the management 
of gastric and esophageal 
adenocarcinoma
First line
The landmark ToGA trial evaluated the combination of 
trastuzumab with a cisplatin/fluoropyrimidine chemotherapy 
doublet in patients with previously untreated, advanced 
HER2-positive gastric or GEJ adenocarcinoma.5 HER2 
status was assessed using both IHC and FISH, and tumors 
were considered HER2 positive on the basis of either an 
IHC 3+ result or FISH amplification showing an HER2/
CEP17 ratio of $2. Among enrolled patients (n=594 of 
the 3807 screened), almost all tumors were FISH positive, 
whereas protein expression by IHC varied (47% 3+, 30% 
2+ and 22% 1+ or 0). Toxicity from the combination of the 
antibody was minimal, and no significant cardiotoxicity 
was reported. The combination of trastuzumab significantly 
improved objective RR, progression-free survival (PFS) 
and OS with the primary end point of median OS improved 
from 11.1 to 13.8 months. A preplanned exploratory analysis 
according to HER2 status suggested that OS was improved 
in patients with high expression of HER2. Patients with the 
strongest expression (IHC 3+) with concomitant FISH gene 
amplification received the greatest benefit, with an abso-
lute improvement in OS of .5 months (12.3 compared to 
17.9 months). IHC expression also appeared to incrementally 
predict for benefit: trastuzumab was most effective in pro-
longing survival in IHC 3+ tumors, less effective in patients 
with IHC 2+ tumors and ineffective in those with HER2 
Figure 3 (A) Gastric cancer specimen showing strong staining in .10% cells (HeR2 3+) illustrating  predominantly basolateral staining pattern. (B) Gastric cancer specimen 
showing faint staining in less than 10% cells (HeR2 0).
Figure 4 HeR2 staining in gastric cancer illustrating tumor heterogeneity within 
specimen with positively (blue arrow) and negatively (red arrow) stained tumor cells.
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gene-amplified (FISH-positive) but nonprotein-expressing 
(IHC 0 or 1+) tumors. Some limited phase II evidence has 
shown that treatment with trastuzumab beyond progression 
with second-line chemotherapy is a safe and potentially effec-
tive treatment option which may have benefit in improving 
PFS; however, this approach is yet to be validated in any 
larger-scale clinical trials.46
Pertuzumab is a monoclonal antibody directed at the 
extracellular domain (ECD) of HER2, preventing receptor 
dimerization. The binding site on domain II is distinct from 
the trastuzumab binding site on domain IV, allowing the 
two antibodies to be effectively delivered together.47 The 
combination of pertuzumab with docetaxel and trastuzumab 
in the first-line treatment of HER2-positive advanced breast 
cancer improved median PFS by ∼6 months, with little 
additional toxicity.48 A phase III evaluation of pertuzumab 
in combination with first-line trastuzumab with cisplatin/
fluoropyrimidine (the JACOB study, NCT01774786) has 
been completed, with results anticipated shortly.
Second line
Trastuzumab-DM1 (T-DM1) is a novel antibody–drug con-
jugate that combines trastuzumab with a microtubule inhibi-
tor and is effective and well tolerated in previously treated 
patients with HER2-positive breast cancer.49 The GATSBY 
phase III study evaluated T-DM1 compared with standard 
taxane therapy for patients with previously treated advanced 
HER2-positive gastric or GEJ cancer, with a preliminary 
report at the 2016 ASCO GI Cancers Symposium suggesting 
a lack of efficacy.11 With 415 patients randomized, median OS 
was 8.6 months with a taxane versus 7.9 months with weekly 
T-DM1. Grade $3 adverse events were numerically lower 
with T-DM1, and rates of serious adverse events and treatment 
discontinuations were comparable between both arms.
Lapatinib is an orally available, small-molecule tyrosine 
kinase inhibitor (TKI) of HER2 and EGFR. In HER2-positive 
advanced breast cancer, lapatinib is licensed in combination 
with capecitabine in the second-line setting; however, it is 
now known to be inferior to single-agent T-DM1.49 Single-
agent lapatinib demonstrated only modest activity in a phase 
II study of unselected patients with advanced gastric cancer, 
but median survival was twice as long in patients with HER2 
amplification (defined as gene copy number greater than the 
median for the cohort) compared with those without.10 Two 
phase III studies of chemotherapy with lapatinib have been 
conducted. The first-line TRIO-013/LOGiC study failed to 
demonstrate a significant improvement in OS when lapa-
tinib was combined with a capecitabine/oxaliplatin doublet, 
although RR and median PFS were significantly improved.12 
There was no correlation between HER2 IHC score and out-
comes. In the second-line TYTAN study, lapatinib combined 
with paclitaxel was compared with paclitaxel alone.13 Again, 
there was no statistically significant OS benefit. A significant 
benefit was, however, detected in a preplanned subgroup 
analysis of patients with the strongest HER2 overexpres-
sion (IHC 3+) in whom median survival was almost double 
compared with chemotherapy alone (14.0 vs 7.6 months), 
while it was not significantly different in those with IHC 
0–2+ tumors. Selected trials of HER2-targeted agents in the 
first- and second-line setting are given in Table 2.
Future directions in HER2 targeting
In early GE cancer, the phase III ST03 study (NCT00450203) 
has been adapted to include baseline HER2 testing and 
randomization of HER2-positive patients to standard periop-
erative chemotherapy with ECX, or the same therapy along 
with lapatinib. The randomized phase II INNOVATION trial 
(NCT02205047) opened in 2015, comparing standard periop-
erative chemotherapy in patients with resectable gastric cancer 
combined with trastuzumab or trastuzumab/pertuzumab.
Moving on from the relative disappointment of lapa-
tinib, a number of multi-receptor-targeting TKIs are under 
Table 1 Comparative criteria for assessing HeR2 protein expression by immunohistochemistry in breast versus Ge cancer
IHC score Breast: surgical resection or biopsy GE: surgical resection GE: biopsy Assessment
3+ Uniform intense membrane staining in 
.10% cells
Strong complete, basolateral 
or lateral membrane staining 
in $10% cells
Strong complete, basolateral 
or lateral membrane staining 
in a cluster of $5 tumor cells
Positive
2+ incomplete or weak/moderate circumferential 
membrane staining in .10% cells, or 
complete and intense circumferential 
membrane staining in ,10% cells 
weak to moderate 
complete, basolateral or 
lateral membrane staining in 
$10% cells
weak to moderate 
complete, basolateral or 
lateral membrane staining in 
a cluster of $5 tumor cells
equivocal
1+ Faint/barely perceptible incomplete 
membrane staining in .10% cells 
Faint membrane staining 
$10% cells
Faint membrane staining in a 
cluster of $5 tumor cells
Negative
0 No staining or faint/barely perceptible 
incomplete membrane staining in ,10% cells
No staining or staining in 
,10% cells
No staining Negative
Abbreviations: Ge, gastroesophageal; iHC, immunohistochemical.
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investigation in the advanced disease setting. Afatinib, a 
multi-kinase inhibitor of EGFR, HER2 and HER4, showed 
signal in a phase II study involving patients with trastuzumab 
refractory disease.50 An expansion cohort looking at safety 
and efficacy in combination with trastuzumab is currently 
recruiting (NCT01522768). Neratinib is a further pan-
HER TKI that has shown promising results in trastuzumab 
refractory HER2-positive breast cancer and is being further 
investigated in a multi-tumor type phase II study involving 
solid tumors (including GE cancer) showing HER2, HER3 
or EGFR mutations (NCT01953926).51 Dacomitinib is an 
irreversible pan-HER TKI that showed a modest efficacy 
signal in a phase II monotherapy study; however, no phase III 
has followed.52
A mechanism of action of increasing interest is tras-
tuzumab’s immune-mediated antibody-dependent cellular 
cytotoxicity via activation of antibody-binding Fc receptors.53 
Murine models have suggested that checkpoint-inhibitor 
immunotherapy could potentiate these immune-mediated 
cytotoxic effects, and the combination is being investigated 
in two clinical trials evaluating trastuzumab with pembroli-
zumab (NCT02318901) and margetuximab (an Fc-optimized 
chimeric second-generation anti-HER2 monoclonal antibody) 
with pembrolizumab (NCT02689284), respectively.54
Challenges in HER2 assessment and 
patient selection
Tumor heterogeneity
The only standardized definition of intratumoral HER2 hetero-
geneity is the ASCO/CAP breast cancer guidance in which it 
is defined as the presence of HER2 amplification in 5%–50% 
of analyzed cells. Applying this definition to GE cancer, an 
HER2 heterogeneity rate of 17% has been reported.55 However, 
heterogeneity in GE cancer has been variably defined, leading 
to large differences in described rates.40,42,56,57 The presence of 
tumor heterogeneity increases the risk of false-negative report-
ing from biopsy samples, and an expert panel of pathologists 
working with the ToGA trial has recommended six to eight 
viable biopsies as necessary for accurate evaluation of HER2 
status.58 At endoscopy biopsies should preferentially be taken 
from the lateral surrounds of the tumor as this area has been 
reported to be more frequently HER2 positive.59
Most studies have reported a high concordance between 
HER2 status in primary tumor and metastatic sites, with a 
concordance rate that varies between 86% and 99%.60–64 The 
GASTHER1 study evaluated the utility of repeat endoscopic 
biopsy in patients whose tumors were initially found to be 
HER2 negative (IHC 0–2+ and ISH negative).65 Repeat 
biopsy identified a “rescue” HER2 positivity rate of 8.7%, 
with 16 HER2-positive tumors identified out of the 183 
retested. Tumors originally classified as IHC 1+ or 2+ were 
more than three times more likely to show HER2 positivity 
on repeat biopsy than IHC 0 tumors, and liver as a site of 
metastasis was almost six times more likely to show HER2 
positivity than reassessment of other metastatic sites. Patients 
found to have HER2 positivity on repeat tumor sampling 
appeared to show similar treatment benefits with trastuzumab 
to those identified as HER2 positive at initial evaluation.65 
In contrast to breast cancer, re-biopsy of newly relapsed 
metastatic sites is not recommended in GE cancer. Data 
such as these, however, suggest that there may be a role for 
re-biopsy in carefully considered selected cases.
Table 2 Selected first- and second-line studies of HER2-targeted therapies in GE cancer
Trial Phase Treatment N ORR (%) PFS (months) OS (months)
First line
ToGA5 iii CX/CF 296 47 5.5 11.1
CX/CF + trastuzumab (FiSH 
positive/HeR2 3+ subgroup)
298 (131) 35 (-) 6.7 (-) 13.8 (17.9)
LOGiC12 iii CAPOX + placebo 273 40 5.4 10.5
CAPOX + lapatinib 272 53 6.0 12.2
HeRBiS-166 ii# S1 + C + trastuzumab 53 68 7.8 16.0
Grávalos et al67 ii# C + trastuzumab 22 32 5.1 –
Second line
GATSBY11 ii/iii Taxane* 117 21 2.9 8.6
T-DM1 228 20 2.7 7.9
TYTAN13 iii Paclitaxel 129 9 4.4 8.9
Paclitaxel + lapatinib (FiSH 
positive/HeR2 3+ subgroup)
132 (52) 27 (-) 5.4 (5.6) 11.0 (14.0)
Notes: #Non-randomized phase ii. *investigator’s choice of either paclitaxel or docetaxel.
Abbreviations: C, cisplatin; CX, cisplatin with capecitabine; CF, cisplatin with 5-FU; CAPOX, capecitabine with oxaliplatin; GE, gastroesophageal; FISH, fluorescent in situ 
hybridization; 5-FU, 5-fluorouracil; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; T-DM1, trastuzumab-DM1.
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IHC versus gene amplification
Although chemotherapy with trastuzumab now represents the 
standard first-line approach for HER2-positive GE cancer, not 
all patients benefit, with variable RRs of ∼30%–60% reported 
(Table 2).5,66,67 Thus, there are a proportion of patients who 
do not respond to trastuzumab therapy, despite their cancer 
conventionally being defined as HER2 positive. The corre-
lation between the magnitude of HER2 gene amplification 
and trastuzumab sensitivity has not been well evaluated in 
GE cancer, with only two exploratory reports on the topic 
published to date. In a 2013 article, Gomez-Martin et al68 
suggested that HER2 gene amplification was a predictive 
factor for trastuzumab sensitivity. A total of 90 patients with 
metastatic gastric cancer treated with first-line chemotherapy 
plus trastuzumab were studied, and optimal HER2/CEP17 
cutoff values for discriminating positive results in terms 
of response and survival were determined using receiver 
operating characteristic (ROC) curve analyses. An HER2/
CEP17 ratio of 4.7 was identified as the optimal cutoff value 
discriminating for response. A more recent 2015 study also 
investigated the association between trastuzumab efficacy 
and HER2 gene amplification and compared its predictability 
according to IHC status.69 A total of 126 patients treated with 
chemotherapy plus trastuzumab were enrolled and HER2 IHC 
score, HER2/CEP17 ratio and HER2 gene copy number were 
analyzed. Patients with IHC 3+ showed significantly longer 
OS than patients with IHC #2+, and an HER2/CEP17 ratio 
of 4.48 was found to be the optimal cutoff for predicting for 
survival (26.9 vs 14.7 months). In a subgroup analysis, the 
treatment outcome of patients with IHC 3+ was not influenced 
by the level of HER2 gene amplification, suggesting that 
further gene amplification testing for this group of patients 
does not provide additional predictive value for clinical 
outcome. However, in patients with IHC #2+, both HER2/
CEP17 ratio and HER2 gene copy number were informative, 
with an HER2/CEP17 ratio of .3.69 and an HER2 gene copy 
number of .7.75 predicting for better outcomes. It is notable 
that these cutoffs are higher than the current standard FISH-
positivity cutoffs of 2 and 6, respectively.
There are high levels of concordance between HER2 gene 
amplification and the highest and lowest protein expression 
groups, with reported ISH positivity rates of 88%–100% 
for IHC 3+ tumors and 0%–8% for IHC 0–1+ tumors.44,56,70 
ToGA screening data show that of those who were clas-
sified as IHC 3+, 94.9% also showed gene amplification 
by FISH.56 The relationship between intermediate IHC 
2+ protein expression and gene amplification, however, 
is less clear. Of the patients with IHC 2+ identified from 
ToGA screening, 54.6% were FISH amplified. There are no 
existing data to suggest mechanisms other than HER2 gene 
amplification to explain the overexpression of the HER2 
protein. Variable results of IHC evaluation have been 
reported dependent upon the IHC techniques used, and 
low IHC results in the presence of amplification may be 
caused by variability in operator-dependent IHC staining 
evaluation.71 The known tumor heterogeneity in GE cancer 
may also contribute, as areas lacking HER2 overexpression 
often exhibit HER2 amplification.71 In cases of equivocal or 
uncertain HER2 expression, the use of amplification level as 
a continuous biomarker may potentially prove to be a more 
robust and rational approach for selecting patients likely to 
benefit from anti-HER2 therapies.
Cardiac risk
There is a lack of consensus, evidence-based guidance for 
the identification, treatment and follow-up of trastuzumab-
induced cardiac dysfunction, with wide variation in practice 
globally.72 Similarly, there are no published guidelines for the 
exclusion of patients with GE cancer for trastuzumab on the 
basis of excess cardiac risk, and many clinicians use the car-
diac eligibility criteria from the main adjuvant trastuzumab 
trials in breast cancer. These were also adopted by the ToGA 
investigators and include congestive heart failure, baseline 
left ventricular ejection fraction (LVEF) ,50%, transmu-
ral myocardial infarction, poorly controlled hypertension 
(.180/100), angina pectoris requiring medication, clinically 
significant valvular heart disease and high-risk arrhythmias as 
contraindications to treatment.5 Cardiac monitoring recom-
mendations for patients with GE cancer also generally follow 
those established for breast cancer, and the UK National 
Institute for Health and Care Excellence (NICE) guidance is 
representative, recommending assessment at three monthly 
intervals with either ECHO or multigated acquisition 
(MUGA) scan. If the LVEF drops by 10 percentage points 
or more from baseline and to below 50%, then trastuzumab 
treatment should be stopped, with a decision to resume based 
on further cardiac assessment and an informed consideration 
of individual risk versus benefit on a case-by-case basis.73 The 
majority of trastuzumab-induced cardiac dysfunction occurs 
during the first 6 months of treatment and onset is rare during 
treatment beyond 6 months or after treatment cessation, thus 
less frequent monitoring may be justified.74 Defining cardiac 
dysfunction through LVEF assessment – particularly with 
the use of MUGA scanning only – may lack sensitivity to 
detect early preclinical changes and other more subtle wall 
motion and valvular pathologies.72
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Current selection standards
Guidelines for selecting patients with GE cancer for trastu-
zumab treatment based upon HER2 testing are not uniform 
worldwide. The ToGA study led to rapid regulatory approval, 
with the US Food and Drug Administration (FDA) approving 
the drug for patients with IHC 3+ HER2 overexpression or 
FISH-confirmed gene amplification (with any IHC expres-
sion), in keeping with the study eligibility criteria. The 
European Medicines Agency (EMEA), however, approved 
the drug in patients with IHC 3+, or IHC 2+ and FISH-
amplified cancers, a subgroup that was assessed in the study 
only as part of an exploratory analysis. In the UK, the NICE 
guidelines recommend the drug for the higher threshold of 
HER2 IHC 3+ tumors only. The 22% of FISH-positive and 
IHC 0–1+ patients in ToGA did not gain significant clinical 
benefit. This suggests that screening for HER2 status by ini-
tial FISH testing may result in a proportion of nonresponders 
being exposed to both the risk and expense of trastuzumab 
unnecessarily. As a result, the EMEA has recommended that 
the initial screening test for HER2 should be with IHC, fol-
lowed by confirmatory FISH testing for IHC 2+ cases only.75 
Conversely, in the UK, NICE guidance mandating treatment 
for IHC 3+ patients only and not taking into account gene 
amplification is almost certainly depriving trastuzumab from 
a subset of patients who would benefit.
Future perspectives: circulating 
biomarkers
Multiple studies have addressed whether circulating HER2 
protein ECD levels (c-ECD) can predict outcome with HER2-
directed treatment.76,77 Baseline c-ECD levels do not appear 
to predict for response, but in a pooled analysis of seven 
trials of first-line trastuzumab with or without chemotherapy 
in patients with breast cancer, those with a 20% or greater 
decline in c-ECD levels over baseline had significantly 
higher RRs, PFS and OS compared with those with a lesser 
degree of decline.77 However, a separate review of 63 stud-
ies concluded that concentrations of HER2 c-ECD are not 
consistently related to patient outcomes.78 Thus, the clinical 
utility of assessing or following c-ECD levels during HER2-
directed therapy is not established and the ASCO expert panel 
on tumor markers in breast cancer has recommended against 
its use in any clinical setting.
Digital polymerase chain reaction (PCR) has the potential 
to accurately quantify the concentration of nucleic acids in a 
sample to a much greater degree than traditional quantitative 
PCR by counting individual DNA molecules.79 The procedure 
requires small concentrations of DNA for accurate analysis 
and thus is well suited to identifying genetic amplifications 
in circulating tumor (ct)DNA, an area under considerable 
study across multiple tumor types.80 In breast cancer, an 
analysis of ctDNA with digital PCR reported high accuracy 
in the determination of HER2 status, with 90% concordance 
with tumor-derived HER2 status in an independent validation 
set.81 In gastric cancer, digital droplet (dd)PCR was used to 
evaluate HER2 amplification in both biopsy specimens and 
circulating tumor (ct)DNA in 25 patients.82 The concordance 
rate between tumor analysis with ddPCR and IHC/FISH 
was high at 92%. The concordance rate with ctDNA was 
lower (62.5%); however, patients who were HER2 positive 
by ctDNA had significantly shorter survival compared with 
HER2-negative patients, suggesting a potential prognostic 
role. A further pilot study has evaluated the ability of ctDNA 
ddPCR to reflect dynamic changes in HER2 during gastric 
cancer treatment and follow-up.83 A total of 60 patients with 
gastric cancer undergoing surgery were followed up with 
sequential analysis of ctDNA. Preoperative HER2 ratio in 
ctDNA correlated well with tumor HER2 status and high 
plasma HER2 ratios were identified in seven out of 13 patients 
at a time point of relapse after prior radical surgery. This 
very early data suggest some promise for the use of ddPCR 
HER2 assessment as a repeatable and noninvasive approach 
for real-time evaluations of HER2 status during treatment; 
however, more work in the area is required.
Discussion
Trastuzumab has been an exemplar for biomarker-driven, 
targeted treatment based on individual tumor biology in GE 
cancer. There remain significant challenges, however, in 
leveraging maximum clinical benefit for patients in a resource-
efficient manner. Uncertainties remain over the optimum 
definition of HER2 positivity and the mandating of ISH 
positivity in IHC 2+ equivocal cases only would seem to be 
more in-keeping with the patterns of clinical benefit seen in the 
ToGA study. It is interesting that both recently reported studies 
investigating the relationship between HER2 gene amplifica-
tion and clinical benefit from trastuzumab came to very similar 
conclusions regarding the optimal HER2/CEP17 ratio predict-
ing for trastuzumab benefit, which was considerably higher 
than the currently mandated FISH definition of positivity.68,69 
Further attempts to target HER2 amplification such as with 
the antibody–drug conjugate T-DM1 and the small molecule 
inhibitor lapatinib have been disappointing. Again, however, 
data from lapatinib studies suggest that it may have a role in a 
subgroup of strongly HER2-expressing patients.10,13
Heterogeneity of HER2 expression in GE cancer is a 
challenging but not an insurmountable problem. Endoscopic 
biopsies, if performed and analyzed to existing standards, 
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can provide reliable HER2 assessment.58 There is relative 
consistency between primary GE tumors and metastatic sites, 
suggesting that, unlike breast cancer, routine re-biopsy of all 
newly relapsed metastatic sites would not be appropriate. 
The GASTHER1 data, however, suggest that in carefully 
selected cases, such as those tumors originally showing IHC 
1+ or 2+ expression and where the relapsed site is in the liver, 
re-biopsy may be indicated to pick up discordant emergent 
HER2 positivity.65
The use of circulating blood biomarkers as a measure 
of HER2 positivity and dynamic response to treatment is 
still very much at an early stage, and whether this results 
in meaningful clinical application has yet to be seen. Such 
circulating biomarkers may offer a noninvasive method of 
ascertaining HER2 status at baseline, while dynamic changes 
in HER2 expression during treatment may shed light on 
resistance mechanisms to HER2-targeted therapy, which are 
poorly understood at present. Moving forward, it is hoped that 
a greater understanding of the relationship between HER2 
protein expression, gene amplification and blood-borne 
biomarkers with treatment response will allow for more 
individualized medical decisions regarding the application 
of HER2 therapies in GE cancer to be made.
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